SCHEMBL1644987

SCHEMBL1644987

O=c1cc(-c2ccccc2)oc2ncccc12

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1B1 Q16678 4/20 0.63
CYP1A2 P05177 4/20 0.63
CYP1A1 P04798 3/20 0.63
TP53 P04637 4/20 0.58
CYP19A1 P11511 4/20 0.58
HPGD P15428 4/20 0.58
ABCB1 P08183 3/20 0.58
CYP3A4 P08684 3/20 0.58
ABCG2 Q9UNQ0 3/20 0.58
TNKS O95271 3/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
GABRP O00591 2/20 0.58
GABRD O14764 2/20 0.58
NPC1 O15118 2/20 0.58
CA12 O43570 2/20 0.58
CA1 P00915 2/20 0.58
CA2 P00918 2/20 0.58
ADORA3 P0DMS8 2/20 0.58
GABRA1 P14867 2/20 0.58
GABRB1 P18505 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13945258 0.89 CYP1A2 (0.56) CYP1B1CYP1A2CYP1A1TP53CYP19A1
Hydrochloric Acid SCHEMBL1647048 0.88 CYP1A2 (0.55) CYP1B1CYP1A2CYP1A1TP53CYP19A1
SCHEMBL311324 0.86 NPC1 (0.60) CYP1B1CYP1A2CYP1A1TP53CYP19A1
SCHEMBL1645950 0.86 EGFR (0.54) CYP1B1CYP1A2CYP1A1TP53CYP19A1
SCHEMBL1644899 0.86 MAOB (0.60) CYP1B1CYP1A2CYP1A1TP53CYP19A1
Hydrochloric Acid SCHEMBL1647034 0.85 EGFR (0.52) CYP1B1CYP1A2CYP1A1TP53CYP19A1
SCHEMBL311707 0.83 TNKS (0.63) CYP1B1CYP1A2CYP1A1TP53CYP19A1
SCHEMBL1645853 0.83 CYP1B1 (0.46) CYP1B1CYP1A2CYP1A1TP53CYP19A1
SCHEMBL311674 0.83 MAOB (0.63) CYP1B1CYP1A2CYP1A1TP53CYP19A1
SCHEMBL311192 0.82 TNKS (0.64) CYP1B1CYP1A2CYP1A1TNKSGABRP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090029987-A1 Pharmaceutical Compositions for the Prevention and Treatment of Complex Diseases and Their Delivery by Insertable Medical Devices RESVERLOGIX CORP. (CA) 2009-01-29 US claimed
EP-1909788-A2 PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF COMPLEX DISEASES AND THEIR DELIVERY BY INSERTABLE MEDICAL DEVICES RESVERLOGIX CORP. (CA) 2008-04-16 EP claimed
WO-2007016525-A2 PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF COMPLEX DISEASES AND THEIR DELIVERY BY INSERTABLE MEDICAL DEVICES RESVERLOGIX CORP. (CA) 2007-02-08 WO claimed
CN-108329325-B Synthesis method of 8-azachromone 天津科技大学 2020-11-10 CN disclosed
CN-108329325-B Synthesis method of 8-azachromone 天津科技大学 2020-11-10 CN disclosed
EP-2314295-B1 Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices RESVERLOGIX INC (CA) 2015-01-28 EP disclosed
US-8410109-B2 Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices RESVERLOGIX CORP. (CA) 2013-04-02 US disclosed
US-8410109-B2 Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices RESVERLOGIX CORP. (CA) 2013-04-02 US disclosed
US-8410109-B2 Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices RESVERLOGIX CORP. (CA) 2013-04-02 US disclosed
EP-2314295-A1 Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices Resverlogix, Inc (CA) 2011-04-27 EP disclosed
US-20090029987-A1 Pharmaceutical Compositions for the Prevention and Treatment of Complex Diseases and Their Delivery by Insertable Medical Devices RESVERLOGIX CORP. (CA) 2009-01-29 US disclosed
US-20090029987-A1 Pharmaceutical Compositions for the Prevention and Treatment of Complex Diseases and Their Delivery by Insertable Medical Devices RESVERLOGIX CORP. (CA) 2009-01-29 US disclosed
US-20090029987-A1 Pharmaceutical Compositions for the Prevention and Treatment of Complex Diseases and Their Delivery by Insertable Medical Devices RESVERLOGIX CORP. (CA) 2009-01-29 US disclosed
EP-1909788-A2 PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF COMPLEX DISEASES AND THEIR DELIVERY BY INSERTABLE MEDICAL DEVICES RESVERLOGIX CORP. (CA) 2008-04-16 EP disclosed
WO-2007016525-A2 PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF COMPLEX DISEASES AND THEIR DELIVERY BY INSERTABLE MEDICAL DEVICES RESVERLOGIX CORP. (CA) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090029987-A1 Pharmaceutical Compositions for the Prevention and Treatment of Complex Diseases and Their Delivery by Insertable Medical Devices VCAM1, ICAM1, TGFB1 CYP1B1 1945/4885CYP1A2 3340/4885CYP1A1 1221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.